Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.

Abstract excerpt

BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are disease-modifying medications for cystic fibrosis (CF) and are shown to be efficacious for only specific CFTR mutations. CFTR mutation frequency varies by ancestry, which is different from but related to demographic racial and ethnic group. Eligibility for CFTR modulator therapy has not been previously reported by race and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cross-Sectional Studies
• Share to Cystic Fibrosis
• Share to Cystic Fibrosis Research Advances